Clinical trial
A Single-arm, Phase II Clinical Trial of Dalpiciclib Combined with Pyrotinib As Second-line Treatment of Advanced Esophageal Squamous Cell Carcinoma
NCT06684600 is registered in ClinicalTrials.gov with Peking University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-arm, Phase II Clinical Trial of Dalpiciclib Combined with Pyrotinib As Second-line Treatment of Advanced Esophageal Squamous Cell Carcinoma
- Lead sponsor
- Peking University
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- November 1, 2024
- Completion date
- October 30, 2027
- Enrollment
- 35 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.